Bill Russell Archives
Mar. 23, 2023—A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.
Jun. 9, 2019—Drug delays onset of type 1 diabetes by two years